MACSprep™ CD3 and CD19 Selection Kit, human was developed for the simultaneous positive selection of CD3+ T cells and CD19+ B cells directly from whole blood.
The indirect magnetic labeling allows to obtain two autologous cell populations using one MACS Column from the same whole blood sample with a plunger free protocol, where target cells are obtained with epitopes free from MicroBeads and Labeling Complexes.
Related products for MACSprep™ CD3 and CD19 Selection Kit, human
MACSprep™ CD3 and CD19 Selection Kit, human was developed for the simultaneous positive selection of CD3+ T cells and CD19+ B cells directly from whole blood.
The indirect magnetic labeling allows to obtain two autologous cell populations using one MACS Column from the same whole blood sample with a plunger free protocol, where target cells are obtained with epitopes free from MicroBeads and Labeling Complexes.
CD3+ T cells and CD19+ B cells are simultanously labeled with Anti-CD3 and Anti-CD19 Labeling Complex, human. Subsequently, Anti-CD3 and Anti-CD19 Complex MicroBeads bind to the corresponding Labeling Complexes on target cells. Then, the cell suspension is loaded onto a MACS Column, which is placed in the magnetic field of a MACS Separator. The magnetically labeled cells are retained within the column. The unlabeled non-target cells flow through; this cell fraction is thus depleted of both CD3+ T cells and CD19+ B cells.
The CD3 and CD19 Bead Release Reagent (50×) usage allows independent sequential release of the MicroBeads from the cells. Target cells are eluted within the magnetic field in a plunger-free workflow.
Optionally, upon the subsequent incubation with the REAlease Release Reagent, the Labeling Complex monomerizes and dissociates from the cell surface leaving the isolated target cells free of all labels.
Isolation of autologous CD3+ T cells and CD19+ B cells directly from whole blood. The isolated CD3+ T cells and CD19+ B cells are well suited for further flow cytometric, cell culture, functional or molecular analysis.
Whole Blood Columns
CD3+ T cells and CD19+ B cells were isolated from whole blood using the MACSprep CD3 and CD19 Selection Kit, human and Whole Blood Columns. Cells were fluorescently stained with the REAfinity Antibody CD45-VioBlue®, CD3-FITC, and CD20-APC and analyzed by flow cytometry using the MACSQuant® Analyzer 16. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. The CD3+ T cell content of the isolated fraction is typically 99,0%±0,6 and the CD19+ B cell content of the isolated fraction is typically 94,2%±2,5 (mean±SD).
The efficient removal of all labels was shown by using Anti-CD3 Labeling Complex for isolated T cells and Anti-CD19 Labeling Complex for B cells to analyze the cells by flow cytometry for the presence of Labeling Complexes. Directly after isolation, the target CD3+ T cells and CD19+ B cells showed positive staining of the respective Labeling Complexes (“MicroBead-free target cells”), whereas after the release of the Labeling Complex, label-free target CD3+ T cells and CD19+ B cells showed negative staining signal similar to the non-labeled cells before separation.
To access a Safety Data Sheet for a hazardous product or component in English or Swedish language, follow the link below and enter the catalog number of the product.
Please note, that the Safety Data Sheet has a cover sheet only in English language.
Should you wish a Safety Data Sheet (SDS) in other languages than English or Swedish, please contact Technical Support.
You have previously chosen International as your location.
What do you want to do?